Till startsida
To content Read more about how we use cookies on gu.se

Volkan Sayin Group

My lab is well positioned in the intersection between lung cancer therapeutics, cancer metabolism and redox biology. Utilizing a lot of expertise, we are now building a precision medicine platform combined with the latest technologies in lung cancer research and metabolomics to establish an extensive translational lung cancer group at Sahlgrenska.

Initially, we plan to identify druggable targets in RAS and RAF driven cancers by combining a high-throughput screening platform using lentiviral-CRISPR/Cas9 strategies that was established during my postdoctoral studies with metabolomics and state-of the art genetically engineered mouse models of lung adenocarcinoma (Sayin VI et al 2017, ELife, & Nat. Med.). We will use lentiviral-CRISPR/Cas9 strategies to inactivate any gene-of-interest at tumor onset or later during tumor progression and metastasis. We will also develop patient-derived xenograft (PDX) models by transplanting fresh human lung tumor pieces subcutaneously in humanized-immunocompromised mice, and then serially transplant them to cohorts of mice for experiments and pre-clinical trials. We will use this platform for a range of experiments in my own group and in collaborative efforts at University of Gothenburg. As an example, we have recently shown that activation of the endogenous antioxidant pathway in lung cancers through genetic or small molecule inactivation of Keap1, rewires cancer cell metabolism and increase cancer progression at the cost of a druggable metabolic dependence on glutaminase. These findings are already fueling ongoing clinical trials and development of novel inhibitors.

The overarching goal of our research is to improve the quality of life and survival rates of cancer patients, guide personalized clinical trials, repurpose pre-existing drugs and to find novel combination therapies that can synergize with current standard of care therapies including chemo- and immune therapies.

New basic understanding of how lung cancer spreads

Article on research by Volkan Sayin (and others) [Swedish Only]

Contact Information

Volkan Sayin


Department of Surgery at Institute of Clinical Sciences
Sahlgrenska Universitetssjukhuset
413 45 Göteborg

Visiting Address:
Blå Stråket 5, Vån 3 SU/Sahlgrenska , 413 45 Göteborg

Page Manager: Mattias Lindgren|Last update: 4/11/2019

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
Utskriftsdatum: 2020-08-10